Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Flows From Operating Activities:
Net loss	$ (33,616)	$ (27,908)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	12,480	14,129
Stock-based compensation	6,604	5,990
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 14)	2,800	2,569
Amortization of deferred financing costs, recorded to interest expense on 2018 Convertible Notes (Note 14)	345	327
Bad debt (recovery) expense	(15)	0
Impairment of intangible assets (Note 3(f))	0	7,160
Unrealized foreign currency exchange loss	3	3,992
Research and development expense recognized for the value of stock issued in connection with milestone achievement (Note 16(b)(xii))	2,419	0
Change in fair value of contingent consideration related to the EVOMELA and Talon acquisitions (Note 9)	1,327	646
Changes in operating assets and liabilities:
Accounts receivable, net	(3,904)	28,966
Other receivables	5,688	(2,757)
Inventories	(4,678)	398
Prepaid expenses	553	1,139
Deferred tax assets	0	(237)
Other assets	(1,374)	(2,991)
Accounts payable and other accrued obligations	(8,353)	(13,052)
Accrued payroll and benefits	(1,697)	(2,645)
Drug development liability	(303)	(1,296)
Acquisition related contingent obligations	(1,300)	0
Deferred revenue	(2,383)	(2,531)
Deferred tax liability	51	184
Other long-term liabilities	1,210	905
Net cash (used in) provided by operating activities	(24,143)	12,988
Cash Flows From Investing Activities:
Redemption of mutual funds	(1)	0
Purchases of property and equipment	(61)	(212)
Net cash used in investing activities	(62)	(212)
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	188	996
Proceeds from sale of stock under employee stock purchase plan	383	335
Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting	(665)	(515)
Payment of contingent consideration related to EVOMELA acquisition (Note 9(b))	(4,700)	0
Proceeds Received (Net of Broker Commissions and Fees )	45,067	0
Dividends paid upon conversion of Series E Convertible Voting Preferred Stock (Note 18)	(6)	0
Net cash provided by financing activities	40,267	816
Effect of exchange rates on cash and equivalents	(44)	(1,263)
Net increase in cash and cash equivalents	16,018	12,329
Cash and cash equivalents—beginning of period	139,741	129,942
Cash and cash equivalents—end of period	155,759	142,271
Supplemental disclosure of cash flow information:
Cash paid for income taxes	11	332
Cash paid for interest	$ 1,650	$ 1,650